Skip to content
Resolve Therapeutics, LLC.
Resolve Therapeutics, LLC.Resolve Therapeutics, LLC.
  • About Us
    • Our Company
    • Management Team
    • Contact Us
  • Product Candidates
    • Our Pipeline
    • RSLV-132
    • Clinical Trials
  • Science
    • Nuclease Therapy Platform
    • Publications
  • Therapeutic Need
    • Sjögren’s syndrome
    • Lupus
    • Patient Resources & Advocacy
  • News
  • About Us
    • Our Company
    • Management Team
    • Contact Us
  • Product Candidates
    • Our Pipeline
    • RSLV-132
    • Clinical Trials
  • Science
    • Nuclease Therapy Platform
    • Publications
  • Therapeutic Need
    • Sjögren’s syndrome
    • Lupus
    • Patient Resources & Advocacy
  • News

News

Resolve Therapeutics Completes Enrollment of Phase 2 Long Covid Clinical Trial

November 14, 2022

St. Petersburg, FL – November 7, 2022 – Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced that its phase 2 clinical trial of RSLV-132 in patients with long covid has been fully enrolled (NCT04944121).

Read more

Resolve Therapeutics Receives FDA Approval to Initiate Phase 2 Clinical Trial of RSLV-132 in Long Covid Patients

June 23, 2021

St. Petersburg, FL–June 23, 2021–Resolve Therapeutics, pioneeringfirst–in–class,targeted, safetherapiesfor underserved autoimmune diseases, today announced that the US Food and Drug Administration has approved a New Investigational Drug application for RSLV–132 to initiate a phase 2 clinical trial in patients with long covid.

Read more

RSLV-132 Demonstrates Clinically Meaningful Improvement in Patients With Systemic Lupus Erythematosus in Phase 2a Clinical Trial

December 8, 2020

RSLV-132 Demonstrates Clinically Meaningful Improvement in Patients With Systemic Lupus Erythematosus in Phase 2a Clinical Trial

Read more

Resolve Therapeutics Publishes Positive Sjögren’s Syndrome Clinical Trial Results

December 8, 2020

Resolve Therapeutics Publishes Positive Sjögren’s Syndrome Clinical Trial Results

Read more

Resolve Therapeutics Announces Completion of Enrollment for Phase 2a Study of RSLV-132 for the Treatment of Lupus

July 22, 2019

Resolve Therapeutics Announces Completion of Enrollment for Phase 2a Study of RSLV-132 for the Treatment of Lupus

Read more

Resolve Therapeutics Announces RSLV-132 Significantly Reduces Fatigue in Phase II Study of Patients with Sjögren’s Syndrome

June 13, 2019

Resolve Therapeutics Announces RSLV-132 Significantly Reduces Fatigue in Phase II Study of Patients with Sjögren’s Syndrome

Read more

Resolve Therapeutics To Present Phase II Data on Lead Product Candidate RSLV-132 at the 2019 EULAR European Congress of Rheumatology

June 10, 2019

Resolve Therapeutics To Present Phase II Data on Lead Product Candidate RSLV-132 at the 2019 EULAR European Congress of Rheumatology

Read more

Resolve Therapeutics Announces Publication of Clinical Data Demonstrating the Role of Circulating RNA in Systemic Lupus Erythematosus

August 22, 2016

Resolve Therapeutics Announces Publication of Clinical Data Demonstrating the Role of Circulating RNA in Systemic Lupus Erythematosus

Read more

Resolve to Present Data on Lupus Studies at International Rheumatology Conference

May 26, 2016

Resolve to Present Data on Lupus Studies at International Rheumatology Conference

Read more

Resolve Announces Positive Clinical Data from RSLV-132 Lupus Study

February 10, 2016

Resolve Announces Positive Clinical Data from RSLV-132 Lupus Study

Read more

Resolve Initiates RSLV-132 Clinical Studies

March 17, 2014

Resolve Initiates RSLV-132 Clinical Studies

Read more

Takeda and Resolve Therapeutics Enter Autoimmune Partnership

February 27, 2013

Takeda and Resolve Therapeutics Enter Autoimmune Partnership

Read more

Resolve Therapeutics Raises $5.8 Million in Private Financing

November 1, 2012

Resolve Therapeutics Raises $5.8 Million in Private Financing

Read more

How to Make Money in Biotech With No Hope of Going Public, Slim Odds of Getting Acquired

May 23, 2011

How to Make Money in Biotech With No Hope of Going Public, Slim Odds of Getting Acquired

Read more

Resolve Announces Series A Financing, New Board Members

May 17, 2011

Resolve Announces Series A Financing, New Board Members

Read more

Resolve Nabs $2M For Lupus Drug, First Step on the Road to Returns With No IPO, No M&A

May 17, 2011

Resolve Nabs $2M For Lupus Drug, First Step on the Road to Returns With No IPO, No M&A

Read more

Resolve and UW Enter Agreement

November 10, 2010

Resolve and UW Enter Agreement

Read more

Resolve featured in Xconomy

November 10, 2010

Resolve featured in Xconomy

Read more

Resolve featured in FierceBiotech

November 10, 2010

Resolve featured in FierceBiotech

Read more
Load more
Resolve Therapeutics
Resolve Therapeutics, LLC
721 1st Ave. N
St. Petersburg, FL 33701
© 2020 Resolve Therapeutics. All rights reserved.

Sitemap   Terms of Use   Privacy Policy  

Go to Top